|Bid||308.10 x 0|
|Ask||308.40 x 0|
|Day's Range||307.00 - 320.60|
|52 Week Range||284.50 - 413.20|
|PE Ratio (TTM)||23.83|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
This highly levered, acquisition-focused growth story has come crashing down recently. It is eerily similar to when the highly-levered, acquisition-focused growth story of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) fell apart not too long ago. As we all know, VRX stock went bust and hasn’t recovered.
The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.
Teva Pharmaceutical Industries Ltd named H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president on Monday, as it struggles with heavy debts and fierce competition for its generic drugs in the United States. Israel-based Teva's shares, which plunged after the company issued poor second-quarter results last month, rose 8 percent in early trade in Tel Aviv. Schultz will succeed Yitzhak Peterburg, who will continue as Teva's interim CEO until Schultz takes over.
Lundbeck CEO Kare Schultz said he's not concerned about the president's tweet on "ripoff prices" aimed at the CEO of Merck.
The healthcare sector has dominated headlines this year thanks to promises from the GOP and the Trump administration related to repealing and replacing Obamacare. This uncertainty has not led to weak trading, and large cap pharma stocks have been among some of the biggest gainers this year. Check out these three large cap pharma stocks to buy now!
Despite the uncertainty looming over the healthcare business, drug stocks have been doing well so far this year. Check out these three large cap pharma stocks to buy now!
Our overall "Medical" sector is up about 7.78% year-to-date, which just edges out the gains of the S&P 500. Within this broad sector, one of the better performing industries has been what we call "Large Cap Pharmaceuticals."
Danish drugmaker Lundbeck raised its financial guidance for the fourth time in 12 months as sales of its anti-epileptic drug Sabril was not dented by copycat competition, as Lundbeck had expected, its chief executive said on Wedneday. * Lundbeck saw an increase in its net cash position of 3 billion crowns.
H. Lundbeck A/S is looking at ways to develop combination therapies for Alzheimer’s disease as the Danish brain-disorder specialist presses forward despite recent failures in late-stage patient trials....
Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer's and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix. The two companies said on Thursday that Lundbeck had made an undisclosed payment to Ossianix, which has labs in Britain, following experiments in mice showing the effective transfer of potential drugs across the blood-brain barrier. Getting modern large-molecule medicines across the barrier that protects the brain is a major challenge for drug developers.